The efficacy and safety of Xialiqi capsule in the treatment of type III prostatitis

A prospective, open-labeled, real world study of the efficacy and safety of Xialiqi capsule in the treatment of type III prostatitis

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100050501

Enrollment

Unknown

Registered

2021-08-28

Start date

2021-09-15

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type III prostatitis

Interventions

Experimental group:Xialiqi capsule

Eligibility

Sex/Gender

Male

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for type III prostatitis; 2. Aged 18 to 50 years.

Exclusion criteria

Exclusion criteria: 1. Patients with acute and chronic bacterial prostatitis and urinary tract infection; 2. Patients with contraindications to drug use; 3. Patients who are participating in clinical trials of other drugs; or who have participated in clinical trials of drugs within the past month; 4. The investigator determines that other patients are not suitable to participate in this clinical study.

Design outcomes

Primary

Measure	Time frame
Chronic Prostatitis Symptom Scale;	—

Countries

China

Contacts

Public ContactSu Xinjun

Zhongnan Hospital, Wuhan University

512100668@qq.com+86 13697326659

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026